Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesJupiter Neurosciences, Inc. Common Stock

Jupiter Neurosciences, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.2 USD 0.07 ( 3.29%)
Last update at 2026-11-06T21:00:00Z
VOLUME
24851
Market Cap
3.97M

Momentum Score

…

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.01
Low
2.27
High
52 Week Price Range
2.88
Low
137.96
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Jupiter Neurosciences, Inc. is a clinical-stage biopharma listed on NASDAQ developing therapies for neurological disorders. Long-term growth may come from clinical program progress, regulatory approvals, strategic partnerships and unmet needs in neurology. Investors may find the company attractive because clinical milestones can materially affect valuation and the focus targets areas with limited treatments.
Key investment risks include early-stage clinical and regulatory uncertainty, limited or no revenue and likely future financing needs, plus competitive and execution risk that could dilute value.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.13
Dividend Yield
-
Revenue TTM
0.06M
Revenue Per Share
0.13
Gross Profit TTM
-1.82M
Debt / Equity
-2.90
ROE
-1888.70%
Net Debt
1.53M
ROCE
486.32%
Diluted EPS TTM
-16.58

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -8.64M -2.44M -4.78M -4.96M -4.20M
Net income -8.64M -2.44M -4.78M -4.96M -4.38M
Selling general administrative 6.84M 2.60M 2.92M 2.72M 3.10M
Gross profit 0.02M - - 0.23M 0.64M
Ebit - -3.09M -3.87M -3.43M -3.91M
Ebitda -8.58M -2.19M -4.56M -4.22M -4.09M
Depreciation and amortization - - -0.69M -0.78M -0.18M
Operating income -8.91M -3.09M -3.87M -3.43M -3.91M
Other operating expenses 8.93M 3.09M 3.87M 3.67M 4.55M
Interest expense 0.07M 0.25M 0.22M 0.74M 0.11M
Interest income 0.00M 0.01M 0.00M 0.00M 0.00M
Net interest income -0.07M -0.24M -0.22M -0.74M -0.11M
Income tax expense - - - - 0.18M
Total revenue 0.02M 0.00M 0.00M 0.23M 0.64M
Total operating expenses 8.93M 3.09M 3.87M 3.67M 4.55M
Cost of revenue 0.00M - - - -
Total other income expense net 0.26M 0.65M -0.91M -1.53M -0.29M
Net income from continuing ops -8.64M -2.44M -4.78M -4.96M -4.20M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 5.56M 6.20M 0.15M 0.24M 0.67M
Other current assets 0.88M 0.88M 0.00M 0.01M 0.12M
Total liab 7.40M 2.03M 5.95M 7.38M 5.85M
Total stockholder equity -1.83M 4.17M -5.80M -7.14M -5.18M
Other current liab 1.94M 1.53M 3.51M 5.29M 4.94M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -34.67M -26.02M -23.58M -18.80M -13.84M
Cash 3.79M 3.77M 0.03M 0.06M 0.33M
Total current liabilities 7.40M 2.01M 5.77M 7.26M 5.68M
Current deferred revenue 0.00M - - - -
Net debt 1.53M -3.55M 2.22M 1.83M 0.32M
Short term debt 5.32M 0.20M 2.07M 1.78M 0.49M
Short long term debt 5.30M 0.15M 2.02M 1.73M 0.44M
Short long term debt total 5.32M 0.22M 2.25M 1.90M 0.65M
Other stockholder equity 32.83M 30.19M 17.78M 11.65M 8.66M
Total current assets 4.82M 4.65M 0.03M 0.07M 0.45M
Net receivables 0.00M 0.00M - - -
Long term debt - - 0.11M - -
Inventory 0.16M 0.00M - - -
Accounts payable 0.13M 0.28M 0.19M 0.19M 0.26M
Non currrent assets other 0.72M 1.48M 0.00M 0.00M 0.00M
Non current assets total 0.74M 1.55M 0.12M 0.17M 0.21M
Capital lease obligations 0.02M 0.07M 0.12M 0.17M 0.21M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Net borrowings 5.43M -2.22M 0.39M 0.98M 0.53M
Total cash from financing activities 5.43M 7.65M 0.45M 0.98M 1.86M
Net income -8.64M -2.44M -4.78M -4.96M -4.20M
Change in cash 0.02M 3.74M -0.04M -0.27M 0.12M
Begin period cash flow 3.77M 0.03M 0.06M 0.33M 0.21M
End period cash flow 3.79M 3.77M 0.03M 0.06M 0.33M
Total cash from operating activities -5.41M -3.91M -0.48M -1.25M -1.74M
Issuance of capital stock 0.00M 9.88M 0.06M 0.00M 0.00M
Depreciation - 0.04M - - -
Change to inventory -0.16M 0.00M - - -
Change to account receivables -0.00M 0.00M - - 0.13M
Other cashflows from financing activities 5.43M 9.88M - - 0.50M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.11M -2.57M 2.35M 1.55M 0.78M
Stock based compensation 2.42M 1.84M 1.20M 0.82M 1.30M
Other non cash items 0.71M -0.75M 0.76M 1.34M 0.38M
Free cash flow -5.41M -3.91M -0.48M -1.25M -1.74M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
JUNS
Jupiter Neurosciences, Inc. Common Stock		 0.07
3.29%		 2.20 - 28.65 61.35 227.66 72.71
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38

Profile*

Jupiter Neurosciences, Inc. Common Stock

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.

1001 North US Highway 1, Jupiter, FL, United States, 33477

561 406 6154

https://jupiterneurosciences.com

5

Name Title Year Born
Mr. Christer Rosen Co-Founder, CEO & Chairman of the Board 1953
Ms. Alison D. Silva MA, MS President, COO & Director 1979
Dr. Marshall Hayward Ph.D. Co-Founder, Chief Scientific Officer & Director 1956
Mr. Alexander Rosen Co-Founder & Chief Administrative Officer 1992
Mr. Saleem Elmasri CPA CFO & Secretary 1987
Dr. Claes Wahlestedt M.D., Ph.D. Co-Founder, Co-Chairman of Scientific Advisory Board & Consulting Chief Medical Officer 1959

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…